Who should benefit from the use of alpha-glucosidase inhibitors?
- 4 October 2007
- journal article
- review article
- Published by Springer Nature in Current Diabetes Reports
- Vol. 7 (5) , 333-339
Abstract
Although most commonly used drugs such as biguanides, sulfonylureas, and more recently, thiazolidinediones, are effective in controlling fasting hyperglycemia, a high percentage of patients have sustained elevated hemoglobin A1c because of persistent elevation of postprandial plasma glucose (PPPG). α-Glucosidase inhibitors (AGIs) specifically target PPPG. AGIs have been shown in several randomized controlled trials to be effective in controlling blood glucose, whether they are used as monotherapy or in combination with other antidiabetic medications. Among the AGIs, acarbose has also been shown to decrease the risk of progressing to diabetes in subjects with impaired glucose tolerance (IGT). Studies have also suggested that acarbose could decrease the risk of cardiovascular disease, both in IGT and in diabetes. Furthermore, AGIs are very safe and are nontoxic drugs. Their only side effects are gastrointestinal, such as flatulence and diarrhea; however, these can be minimized by the “start low, go slow” approach. AGIs should be considered whenever postprandial hyperglycemia is the dominant metabolic abnormality.Keywords
This publication has 41 references indexed in Scilit:
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose toleranceEuropean Journal of Clinical Investigation, 2005
- α-Glucosidase Inhibitors for Patients With Type 2 DiabetesDiabetes Care, 2005
- Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose ToleranceStroke, 2004
- The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.Diabetes Care, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- An Importance of Carbohydrate Ingestion for the Expression of the Effect of α-Glucosidase Inhibitor in NIDDMDiabetes Care, 1996
- A Double-Blind Placebo-Controlled Trial Evaluating the Safety and Efficacy of Acarbose for the Treatment of Patients With Insulin-Requiring Type II DiabetesDiabetes Care, 1995
- Efficacy of 24-Week Monotnerapy With Acarbose, Glibenclamide, or Placebo in NIDDM Patients: The Essen StudyDiabetes Care, 1994